A 32-year-old female (weight 64 kg) presents with a new prescription for pregabalin (Schedule V federally; controlled in many states) 150 mg orally twice daily for neuropathic pain. She currently takes oxycodone immediate-release (Schedule II) 10 mg every 6 hours as needed (uses 4/day) and baclofen 10 mg three times daily. Allergies: none. Medical history: diabetic neuropathy, type 2 diabetes; no substance use disorder. Labs: serum creatinine 2.0 mg/dL (0.6–1.3), estimated creatinine clearance 28 mL/min. Which action should the pharmacist take regarding this prescription?
- Dispense pregabalin 150 mg twice daily as written because renal adjustment is not necessary
- Contact the prescriber to recommend a reduced pregabalin dose due to renal impairment and counsel on additive sedation/respiratory depression risk with opioids (correct answer)
- Recommend increasing oxycodone dose to offset pregabalin-related dizziness
- Advise storing pregabalin in the freezer to maintain potency and prevent misuse
Explanation: This question assesses dose adjustments for pregabalin in renal impairment when combined with opioids. The key patient-specific factors are the reduced creatinine clearance of 28 mL/min and concurrent oxycodone, necessitating pregabalin dose reduction to avoid accumulation and additive sedation. Option B is the best choice as contacting the prescriber for adjustment and counseling on risks ensures safe use and prevents respiratory depression. Option A is incorrect because renal adjustment is required per labeling, a common oversight. Option C is suboptimal as increasing oxycodone worsens risks; option D provides improper storage advice. A clinical pearl is that pregabalin doses should be halved for CrCl <30 mL/min. Implement a decision framework calculating CrCl and screening for CNS depressant interactions in controlled substance prescribing.